Last reviewed · How we verify

NCT01638663

Effect of Vasopressin Antagonism on Renal Sodium and Water Handling and Circulation During Inhibition of the Nitric Oxide System in Healthy Subjects

Completed Phase 2 Last updated 8 October 2014
What this trial tests

Phase 2 trial testing Tolvaptan in Cardiovascular Diseases in 20 participants. Completed in 1 March 2014.

Timeline
1 May 2012
Primary endpoint
1 March 2014
1 March 2014

Quick facts

Lead sponsorRegional Hospital Holstebro
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposetreatment
Enrollment20
Start date1 May 2012
Primary completion1 March 2014
Estimated completion1 March 2014
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Regional Hospital Holstebro

Who can join

Adults 18 to 40, any sex, with Cardiovascular Diseases or Nephropathy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to investigate the effect of tolvaptan on renal water, sodium and potassium excretion, plasma concentration of vasoactive hormones,central blood pressure, pulse wave velocity (PWV) and augmentation index, basal and during inhibition of nitric oxide synthesis in healthy subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tolvaptan

Trials testing the same drug.

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other Regional Hospital Holstebro trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01638663.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing